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Abstract
Bone metastases are severely debilitating and have a significant impact on the quality of life of women with
metastatic breast cancer. Treatment options are limited and in order to develop more targeted therapies, improved
understanding of the complex mechanisms that lead to bone lesion development are warranted. Interestingly, whilst
prostate-derived bone metastases are characterised by mixed or osteoblastic lesions, breast-derived bone
metastases are characterised by osteolytic lesions, suggesting unique regulatory patterns. This study aimed to
measure the changes in bone formation and bone resorption activity at two time-points (18 and 36 days) during
development of the bone lesion following intratibial injection of MDA-MB-231 human breast cancer cells into the left
tibiae of Severely Combined Immuno-Deficient (SCID) mice. The contralateral tibia was used as a control. Tibiae
were extracted and processed for undecalcified histomorphometric analysis. We provide evidence that the early bone
loss observed following exposure to MDA-MB-231 cells was due to a significant reduction in mineral apposition rate,
rather than increased levels of bone resorption. This suggests that osteoblast activity was impaired in the presence of
breast cancer cells, contrary to previous reports of osteoclast-dependent bone loss. Furthermore mRNA expression
of Dickkopf Homolog 1 (DKK-1) and Noggin were confirmed in the MDA-MB-231 cell line, both of which antagonise
osteoblast regulatory pathways. The observed bone loss following injection of cancer cells was due to an overall
thinning of the trabecular bone struts rather than perforation of the bone tissue matrix (as measured by trabecular
width and trabecular separation, respectively), suggesting an opportunity to reverse the cancer-induced bone
changes. These novel insights into the mechanisms through which osteolytic bone lesions develop may be important
in the development of new treatment strategies for metastatic breast cancer patients.
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Introduction
Breast cancer is the most common form of cancer in females
worldwide and is the second most common cause of cancer-
related deaths for Australian and North American women [1,2].
In approximately 70% of patients in the advanced stages of
breast cancer, the cancer cells move preferentially to the
skeleton [3]; and once metastasised, survival rate decreases
significantly as no cure is currently available [2].
Throughout adult life, the human skeleton is continuously
remodelled by microscopic patches of bone resorption
(degradation) by osteoclasts, which is coupled with bone
formation by osteoblasts at the same site [4]. In healthy bone
tissues, these two phases are tightly regulated and occur in a
balanced sequence, such that bone tissue quality and bone
mass are preserved [5]. The remodelling balance is disrupted
when metastatic breast cancer cells invade and grow within the
bone microenvironment, resulting in the development of
metastatic bone lesions that cause the bones to become fragile
and therefore fracture more easily [6]. In most breast cancer
patients, the bone lesions which develop are characterised by
a decrease in bone mass as a result of tumour growth and are
termed osteolytic bone lesions [7]. The lesions that form are
debilitating because they are primarily in the load-bearing
bones of the body, such as the long bones, vertebral column
and bony pelvis [8]. Despite the clinical importance of bone
metastasis, the mechanisms that lead to the development of
metastatic bone lesions in breast cancer patients are not
clearly defined.
Bone histomorphometry is the microscopic analysis of the
morphology and organisation of bone tissue. It is commonly
used to evaluate metabolic changes in bone tissues including
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changes in bone density, structural re-organisation of the bone
matrix, as well as dynamic measurements of bone formation
and bone resorption activities [9,10]. Nevertheless, previous
studies in the field of breast cancer bone metastases have
failed to utilise histomorphometry effectively to define the
changes in bone formation and bone resorption activities that
occur during osteolytic bone lesion development with a limited
number of studies using endpoint data from post-mortem
samples and patients with debilitating fractures [7,11].
Osteoclast number has been analysed repeatedly as a
measure of resorptive activity during metastatic lesion
development in animal models [12-16] but this form of analysis
assumes that all osteoclasts participate equally in the bone
resorption process. The proportion of the bone surface
undergoing resorption can provide a more accurate method of
determining osteoclast activity [9].
Bone loss can occur through three different mechanisms, all
of which occur due to unbalancing of the bone remodelling
cycle: (i) increase in bone resorption activity; (ii) decrease in
bone formation activity; or (iii) a simultaneous increase in bone
resorption and a decrease in bone formation. Given that
changes to the rate of bone formation have not been subjected
to dynamic measurements in previous studies in this field, it is
unclear how osteolytic bone lesions develop in breast cancer
bone metastases. In most studies, the decrease in bone mass
was attributed to an overall increase in bone resorption, as
suggested by an increase in osteoclast number [14,15,17,18].
However, recently molecular profiling and osteoblast number
analysis has suggested that the bone loss in osteolytic lesions
may be due to a concomitant decrease in bone formation
activity [14,19,20,21]. Furthermore there is in vitro evidence
that the co-culturing of MC3T3-E1 pre-osteoblastic cells with
MDA-MB-231 breast cancer cells results in a reduction in
osteoblast differentiation, adhesion properties, mineralisation
and increased apoptosis [22]. Therefore there is compelling
evidence that breast cancer cells modulate the function of both
osteoblasts and osteoclasts. However in vivo studies
investigating the effect of breast cancer cells on osteoblast
function and bone mineralisation are still lacking.
This study aimed to measure the changes in osteoblastic
and osteoclastic activity within bone tissue of immunodeficient
mice at two different time-points following intratibial injection of
the MDA-MB-231 human breast cancer cell line. From the
histomorphometric analysis, there is evidence to suggest that
the early stages of osteolytic bone lesion development occurs
primarily by retardation of the bone formation response – as
indicated by a significant decrease in osteoblastic activity in the
cancer cell-injected limb. This contrasts with the current
assumption that the decrease in bone mass associated with
breast cancer osteolysis is primarily due to increased bone
degradation. Although further work is needed with other
osteolytic breast cancer cell lines to confirm this observation,
the result of this study may have significant implications for the
development of treatments that aim to reduce the severity and
occurrence of metastatic bone lesions in breast cancer
patients.
Materials and Methods
Tissue culture
MDA-MB-231 cells (American Type Culture Collection,
Rockville, MD, USA) were cultured in DMEM medium
(Invitrogen, Mt Waverly, Victoria, Australia) and supplemented
with 10% foetal calf serum (Invitrogen) and 100 units/mL
penicillin G sodium and 100 µg/ml streptomycin sulphate
(Invitrogen). The cells were tested to be free from Mycoplasma
contamination using the Takara PCR Mycoplasma Detection
Set (Takara Bio, Madison, Wisconsin, USA).
MDA-MB-231 cells were grown to 70-80% confluence for
viability determination. The cells were detached using EDTA,
resuspended and placed on ice to mimic storage of the MDA-
MB-231 cells on the day of surgery. The viability of the cells
was determined at 30 minute intervals over a 3-hour period
using the Trypan Blue exclusion method and a Neubauer
haemocytometer (Brand GMBH+ CO KG, Wertheim,
Germany).
Ethics statement and Intratibial injection of cancer cells
Six week old female SCID mice (n=10 per time-point) were
housed under a specific pathogen free environment at the
Princess Alexandra Hospital Biological Research Facility and
had constant access to standard mouse pellets and water. This
study received ethical approval from the Queensland University
of Technology animal ethics committee (approval number:
070000061) with ratification from the University of Queensland
animal ethics committee (#168/07). Mice were provided with
enrichment during the course of the study including sunflower
foraging and cardboard for shredding and nesting behaviour.
All efforts were made to minimise suffering during the surgical
procedure.
Prior to surgery, the animals were anaesthetised by
intraperitoneal injection of ketamine (Parnell) and xylazil-20
(Ilium) in sterile water (at a ratio of 3:2:25). With the knee joint
flexed, a 26-gauge needle was inserted transcutaneously
through the patellar ligament and into the proximal tibial
metaphysis. Ten microLitres of the cancer cell suspension at a
concentration of 5 x 106 cells/mL PBS was injected into the left
tibia. PBS alone was injected as a vehicle into the contralateral
limb using the same procedure to account for a possible bone
adaptation response from tissue irritation caused by the needle
entry. Based on the viability assay we found that 80% of the
MDA-MB-231 cells were viable 3 hours after detachment from
the culture flask, which was sufficient time to complete all
surgeries (n=10) each day.
Radiography
Given that the bone remodelling cycle is around 16-20 days
in mice [23], the mice were randomly allocated to two different
time-point groups -18 days or 36 days post-injection - to
examine changes in bone tissue architecture across two
remodelling cycles. For dynamic histomorphometry, the
calcium-binding fluorochrome label calcein (1mg/mL; Sigma
Chemical Co, St Louis MO, USA) was delivered by
intraperitoneal injection at a dose of 10mg/kg into each animal
at 7 and 2 days before euthanasia to give a 5 day inter-label
Osteoblast-Dependent Breast Cancer Bone Osteolysis
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period. All mice were euthanized by carbon dioxide overdose
and the left and right hindlimb of each animal was imaged
using the Kodak Image Station: in vivo FX (Eastman Kodak
Company, Rochester, NY, USA) to determine whether
radiographically visible lesions had formed.
Resin Embedding and Structural Histomorphometric
Analysis
The left and right tibiae were isolated and fixed in 10%
neutral buffered formalin and embedded in methyl-
methacrylate. Thick longitudinal sections (70-100µm) were cut
from each tibia using a diamond-blade microtome (Leitz 1600
Saw Microtome, Leica, Wetzlar) and mounted unstained on
glass slides for light and fluorescence microscopy using a
Zeiss Axio Imager Z1M fluorescent microscope (Carl Zeiss
Inc., North Ryde, NSW, Australia) at a magnification of x200.
Digital photomicrographs of the proximal metaphysis were
taken using a Zeiss MRc5 camera and AxioVision software
(Carl Zeiss Inc.) and analysed using ImageJ software (National
Institute of Health, USA). The following variables – abbreviated
according to Parfitt et al. [9] – were measured in each section:
trabecular area (Tb.Ar); tissue area (T. Ar); trabecular
perimeter (Tb.Pm); resorption perimeter (Rs.Pm); double-
labelled perimeter (dL.Pm); single-labelled perimeter (sL.Pm);
and inter-label width (Ir.L. Wi). Only secondary spongiosa in
the proximal tibial metaphysis were measured in a
representative region 450µm distal to the epiphyseal growth
plate and extending 900µm distally. From this information, a
range of histomorphometric indices were calculated using the
formulae in Table 1 [24,25].
Paraffin Embedding and Cellular Histological Analysis
An additional three animals were inoculated with MDA-
MB-231 cells in the right tibia and sacrificed at 36 days post-
injection. Tibiae were extracted, fixed and decalcified in EDTA
for paraffin embedding. Thin longitudinal sections (4µm) were
cut using a rotary microtome (Leica RM2235) and stained with
tartrate resistant acid phosphatase (TRAP) and counterstained
with Mayer’s haematoxylin. Osteoclasts were identified as
TRAP-positive, multinucleated cells on the trabecular bone
surface. The number of osteoclasts per trabecular bone
perimeter (N. Oc/Tb.Pm) and percentage of bone surface lined
by osteoclasts (Oc.S/BS) was calculated in the proximal
metaphysis (same representative region measured as
described for structural histomorphometric measurements
above) using a Nikon Eclipse Ci Fluorescent Microscope with a
x 20 objective and Osteomeasure software (Osteometrics Inc.,
Atlanta, Georgia, USA). In addition immunostaining with Anti-
NuMA primary antibody (rabbit polyclonal anti-human NuMA,
1:100, EPITOMICS®, S2825) and Peroxidase-labelled dextran
polymer conjugated goat anti-mouse secondary antibody
(Dako, Australia, K406189) was conducted to aid identification
of human-specific cells in the mouse, namely the injected
MDA-MB-231 cells.
Statistical Analysis
All histomorphometric data were analysed for statistical
significance using the SPSS statistics package (SPSS Inc.,
Chicago, Illinois) by a one-way analysis of variance where we
allocated the factorial treatment combinations to treatments of
a single factor with equal variance being assumed. Variance
homogeneity was confirmed by determining that the ratio of the
largest standard deviation to the smallest standard deviation
was not greater than 4 for each dependent variable [26,27].
Significance was accepted at P < 0.05, while probability levels
Table 1. Formulae for the calculation of histomorphometric
indices and the meaning of each index.
Histomorphometric
index Formula for calculationA
Interpretation of the
indexB
Percentage
trabecular area
(%Tb.Ar, %)
Tb.Ar/T.Ar x
100
The proportion of tissue area
containing trabecular bone tissue.
Trabecular width
(Tb.Wi, μm)
(2000/1.199) x
(Tb.Ar/Tb.Pm)
An architectural measurement that
describes the average width of each
trabecular bone piece.
Trabecular number
(Tb.N, n/mm)
(1.199/2) x
(Tb.Pm/T.Ar)
An architectural measurement that
describes the number of trabecular
bone pieces present in the tissue
area. High Tb.N indicates
fragmentation of the bone matrix (if
Tb.Sp is also high); whereas a low
Tb.N indicates connectivity between
the trabecular pieces (if Tb.Sp is also
low or unchanged).*
Trabecular
separation (Tb.Sp,
μm)
(2000/1.199) x
(T.Ar – Tb.Ar)/
Tb.Pm
An architectural measurement that
describes the distance between each
trabecular bone piece and indicates
the looseness of the bone tissue
matrix.*
Mineralising surface
(MS, %)
(dL.Pm +
sL.Pm/2)/
Tb.Pm x 100
An indicator of the number of active
osteoblasts over the bone surface.
Mineral apposition
rate (MAR, μm/day) Ir.L.Wi/5
An indicator of osteoblast activity by
determining the rate at which
osteoblasts are laying down new
bone matrix.
Bone formation rate
per surface (BFR/BS,
μm2/μm3/d)
MS x MAR x
3.65
An indicator of the overall osteoblast
contribution to the observed bone
changes and is a combination of both
osteoblast number and osteoblast
activity.
Bone formation rate
per unit area (BFR/
B.Ar, %/y)
(sL.Pm/2 +
dL.Pm) x MAR/
Tb.Ar x 365 x
100
Considered to be the rate of bone
remodelling or bone turnover.
Resorption surface
(Rs.S, %)
Rs.Pm/Tb.Pm
x 100
An indicator of osteoclast activity, as
determined by the proportion of the
bone surface undergoing resorption.
*. Tb.N and Tb. Sp need to be considered together to understand trabecular spatial
orientation.
A = Formulae as described by Li et al. 1990 (22)B = Meaning of each index based
on Parfitt et al. 1983 (23)
doi: 10.1371/journal.pone.0068103.t001
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between 0.05 and 0.1 were classified as marginal if the
difference between the means was greater than twice the
standard error of the mean.
Real time PCR profiling of cell lines
Total RNA was isolated from the MDA-MB-231 cell line (RNA
from LNCaP cell line used as a negative control), using TRIzol
(Invitrogen) and purified using the RNeasy Mini Kit (QIAGEN,
Australia) as per the manufacturers’ instructions. Reverse
transcription and cDNA synthesis was performed using
Superscript III (Invitrogen). Gene-specific oligonucleotide
primers were designed based on cDNA sequences derived
from the NCBI sequence database and using Primer Express
software (Applied Biosystems, Scoresby, Victoria, Australia).
Primers manufactured by Sigma-Proligo (Castle Hill, Australia)
were 5’-CCCATCCAGTACCCCATCATT-3’ (sense) and 5’-
CCAAGATCCAACTACGAGCTTTTT-3’ (antisense) primer
sequences for human noggin and 5’-
ACCATTGACAACTACCAGCCGT-3’ (sense) and 5’-
GGAATACCCATCCAAGGTGCTAT-3’ (antisense) primer
sequences for human DKK-1 expression. PCR reactions were
conducted on an ABI Prism 7000 Thermal Cycler (Applied
Biosystems) using the SYBR green dye detection system as
per the manufacturer’s instructions. For each cell line, the
reaction was performed in triplicate for two separate cDNA
samples and relative levels of gene expression were
normalised to 18S ribosomal RNA primers (5’-
GATCCATTGGAGGGCAAGTCT-3’, sense and 5’-
CCAAGATCCAACTACGAGCTTTTT-3’, antisense).
Results
Qualitative analysis of bone lesion development
At sacrifice, an appreciable bone loss was only detected in
three animals from the 36 day post-injection group using
radiography (Figure 1). Despite this, 15 of the 20 animals had
in fact developed osteolytic lesions based on a >20% reduction
in the percentage trabecular area (%Tb.Ar) measured by
histology. Qualitatively, there was increased blood supply and
a reduction in the amount of trabecular bone tissue in the
proximal tibial metaphysis of the cancer-injected limb
compared to the vehicle control. NuMA immunohistochemical
staining demonstrated the presence of multiple small colonies
of MDA-MB-231 cells residing in the proximal metaphysis of
paraffin embedded samples indicating an early stage of
osteolysis at 36 days post-MDA-MB-231 cell injection. In the
three animals that developed overt radiographical lesions, the
cortical bone of the proximal tibial metaphysis of two mice was
completely perforated (Figure 1D), suggesting the invasion of
cancer cells into the surrounding soft tissues.
Quantitative histomorphometric analysis of osteolytic
tumour lesions
Quantitatively, the histomorphometry data (Table 2) indicated
that the cancer-injected limb had a statistically significant lower
percentage trabecular area (%Tb.Ar) (4.56% ± 1.05) compared
to the control limb (9.51% ± 1.45) at 36 days post-injection (p =
0.045) and compared to the cancer-injected limb at 18 days
post-injection (10.37% ± 1.29; p = 0.014). These data indicate
that the loss in trabecular bone area within the cancer-injected
limbs increased with time and became significant at 36 days
post-injection (Figure 2).
Associated with this decrease in percentage trabecular area
was a significant decrease in the trabecular width (Tb. Wi). The
Tb. Wi was significantly lower (p = 0.041) in the cancer-injected
limb (24.03µm ± 4.35) compared to the control limb (36.99µm ±
2.88) at 36 days post-injection and Tb. Wi significantly declined
in the cancer-injected limbs between 18 and 36 days (p =
0.035) (Figure 2).
Trabecular number (Tb.N) or fragmentation of the bone
matrix was marginally lower in the cancer-injected limbs
(2.72n/mm ± 0.27) compared to the control limbs (4.07n/mm ±
0.58) at 18 days post-injection (p = 0.072) (Table 2, Figure 2).
In addition, the trabecular number had significantly decreased
(p = 0.025) in the control limbs at 36 days (2.48n/mm ± 0.26)
compared to 18 days post-injection. When considering this
result in conjunction with no significant change in trabecular
separation (Tb. Sp, distance between each trabecular bone
piece) being observed, it suggests increased trabecular
bridging occurred in the control animals as an age-related
phenomenon resulting in increased interconnectivity. The
reduction in Tb.N is consistent with the fact that juvenile
animals were used in this study and that longitudinal bone
Table 2. Histomorphometric indices of bone remodelling in
the proximal tibial metaphysis of female SCID mice
following injection of PBS (Control) or MDA-MB-231 breast
cancer cells.
 
Control -18
days
MDA-MB-231
-18 days
Control -36
days
MDA-MB-231
-36 days
%Tb.Ar (%) 11.510 ±1.283
10.367 ±
1.288 9.508 ± 1.454
4.559 ± 1.053 *,
#
Tb. Wi (μm) 30.334 ±3.122
37.338 ±
2.583
36.988 ±
2.882
24.026 ± 4.346
*, #
Tb.N (n/mm) 4.074 ± 0.579 2.724 ±0.265Δ
2.481 ±
0.256§ 1.469 ± 0.311
Tb. Sp (μm) 255.594 ±38.570
370.747 ±
51.254
400.885 ±
42.487
488.410 ±
122.229
MS (%) 13.209 ±1.347
14.950 ±
1.090
13.138 ±
2.416 11.956 ± 3.011
MAR (μm/d) 1.343 ± 0.134 0.908 ± 0.123 1.035 ± 0.160 0.437 ± 0.111 
*,
¶
%Rs.S (%) 8.125 ± 1.191 7.790 ± 0.974 6.830 ± 0.906 5.347 ± 1.372
BFR/BS
(μm2/μm3/d)
63.528 ±
8.566
51.634 ±
8.651
53.573 ±
12.617
28.593 ±
11.231
BFR/B.Ar
(%/y)
365.044 ±
44.884
237.287 ±
44.058
222.312 ±
46.618
160.278 ±
68.936
The animals were sacrificed at 18 days (time-point 1) or 36 days (time-point 2)
post-injection. Values are Mean ± SEM (n = 10). * p < 0.05 vs PBS-injected limb at
36 days; #, p < 0.05 vs MDA-MB-231 injected limb at 18 days; ¶ p = 0.079 vs
MDA-MB-231 injected limb at 18 days; Δ, p = 0.072 vs PBS-injected limb at 18
days; § p < 0.05 vs PBS-injected limb at 18 days.
doi: 10.1371/journal.pone.0068103.t002
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growth was still occurring to increase the connectivity between
each trabecular bone piece.
No statistical significance was observed in the index
mineralising surface (MS) between the cancer-injected and
control limbs at both 18 days and 36 days post-injection (Table
2). Given that MS is an indicator of the number of active
osteoblasts on the surface of trabecular bone, our observation
indicates that the number of osteoblasts participating in bone
formation has not changed significantly between the treatment
groups.
Interestingly, the mineral apposition rate (MAR) was
significantly lower in the cancer-injected limb (0.44µm/d ± 0.11)
compared to the control limb (1.04µm/d ± 0.16) at 36 days
post-injection (p = 0.016) but not at 18 days post-injection
(Table 2; Figure 2). There was also a marginally significant
decline (p = 0.079) in MAR within the cancer-injected limb at 36
days compared with 18 days post-injection (0.91µm/d ± 0.12).
Figure 1.  Radiographic appearance of osteolytic tumour lesions resulting from intratibial injection with MDA-MB-231
breast cancer cells.  Lateral projection of mouse hindlimb demonstrating establishment of an osteolytic tumour lesion at 18 days
(A) and 36 days (B-D) post-injection with PBS (control: B) or MDA-MB-231 cells (C and D). White circle in C, area with increased
bone loss, only seen in 33% of animals at 36 days. Arrows in D indicate area of cortical perforation seen in 20% of animals at 36
days.
doi: 10.1371/journal.pone.0068103.g001
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This indicates that there was a reduction in the activity of
individual osteoblasts in the cancer-injected limb and that this
reduction increased with time to become statistically significant
at 36 days post-injection. Although there was a trend to
suggest that the bone formation rate per surface (BFR/BS) was
lower in the cancer-injected limbs compared to the control
limbs at 36 days post-injection (Table 2), the difference
between the two treatment groups did not reach statistical
significance. This is not surprising since this index is calculated
by the combined MS and MAR scores and MS was not found
to be significantly different between cancer and control limbs.
There was no statistical difference between the cancer-
injected and control limbs at both time-points for resorption
surface (Table 2), suggesting that osteoclast activity, as
indicated by the percentage of trabecular perimeter containing
resorption pits, did not differ significantly between the cancer-
injected and control limbs. Results from the TRAP-stained
bone sections (n=3) resulted in no significant differences in the
number of osteoclasts per bone surface or the percentage of
bone surface lined by osteoclasts (p>0.18) between the
tumour-bearing and control limbs. Interestingly though, there
was a trend towards lower osteoclast numbers in the cancer-
injected limbs (mean N.Oc/BS 8.90/µm ±2.97 in control limb
compared to 4.21/µm ±4.34 in tumour-bearing limb; mean
Oc.S/BS 35.34% ±19.98 in control limb compared to 12.26%
±9.56 in tumour-bearing limb) despite the significantly reduced
percentage trabecular area seen in these animals; this
difference however did not reach significance due to the small
sample size allocated to paraffin embedding in this study.
Furthermore, no statistical significance was observed in bone
formation rate per unit area (BFR/B.Ar) between the cancer-
injected and control limbs at both time-points (Table 2),
suggesting that the rate of bone remodelling is not significantly
affected by the presence of MDA-MB-231 breast cancer cells.
MDA-MB-231 cells express Noggin and DKK-1 in vitro
Given that the observed bone loss in this study was linked to
decreased osteoblast activity, and that osteoblast inhibitors
have been implicated in pathologic bone loss [28-30], we
questioned whether the MDA-MB-231 cells express inhibitors
which could potentially suppress osteoblast activity.
Specifically, we were interested in the expression of
antagonists against the Wnt proteins and bone morphogenetic
proteins (BMPs), which are important regulators of osteoblast
Figure 2.  The effect of MDA-MB-231 cells on bone indices at 18 days and 36 days post-surgery.  Control limbs were injected
with PBS. Values presented are the Mean ± SEM for 10 mice from each time-point. *, significantly different from control limb at 36
days (p < 0.05); Δ, significantly different from MDA-MB-231 injected limb at 18 days (p < 0.05); ß, marginally different from MDA-
MB-231 injected limb at 18 days (p < 0.8); #, marginally different from control limb at 18 days (p < 0.8); α, significantly different from
control limb at 18 days (p < 0.05).
doi: 10.1371/journal.pone.0068103.g002
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activity and proliferation [30,31]. With this in mind, we screened
the MDA-MB-231 cell line for the Wnt-antagonist, Dickkopf
Homolog 1 (DKK-1), and the BMP-antagonist noggin (NOG),
using real-time PCR. We also screened the prostate cancer
cell line LNCaP as a negative control on the premise that this
cell line forms osteoblastic tumour lesions in bone [32]. We
found that the MDA-MB-231 cell line expressed DKK-1 and
noggin mRNA (1.78x10-5 ±1.92x10-6 and 4.75x10-7 ±7.39x10-8
normalised to 18S RNA levels, respectively); whereas the
LNCaP cell line did not express these factors.
Discussion
Breast cancer patients commonly develop metastatic bone
lesions which are severely debilitating.Despite its clinical
significance, the mechanisms through which breast cancer
cells interact with the bone microenvironment to drive the
development of bone loss are only starting to emerge in the
literature. Previous studies have failed to clarify the changes to
the rates of bone formation and bone degradation in the
presence of breast cancer cells. Using bone histomorphometry,
we report for the first time the temporal changes to the
activities of the bone-forming osteoblasts and the bone-
resorbing osteoclasts during the development of osteolytic
tumour lesions in an animal model using intratibial injection of
MDA-MB-231 cells.
In our model, 15 of the 20 animals had an appreciable
decrease in %Tb.Ar in the cancer-injected limbs compared to
their respective controls as determined by histomorphometry.
Nevertheless, most animals developed lesions that were
difficult to observe from radiography with only three animals
developing radiographically overt lesions, in which a significant
degree of trabecular bone loss and cortical bone perforation
could be observed macroscopically. This suggests that plain
radiography is not sufficiently sensitive to detect early changes
in trabecular bone mass. Nevertheless, in most animal models
of breast cancer bone metastasis, the degree of bone loss has
been determined by measuring the osteolytic lesion area on
radiographs using computer-automated grey-level density
measurements [15,16,33]. This is an important limitation to
their estimated values, because to obtain accurate and
quantitative measures of trabecular bone loss, particularly for
subtle changes, bone histomorphometry is required.
Results from the histomorphometric analysis indicated that
there was a significant reduction in trabecular bone area in the
presence of MDA-MB-231 cells at 36 days post-injection and
that the extent of bone loss increased with time; which supports
the findings of previous studies [13,34] where a decrease in
trabecular bone area was observed following intratibial
implantation of MDA-MB-231 cells. Our results also indicate
that significant evidence of bone loss only occurred following
two bone remodelling cycles, given that there was no
significant reduction in %Tb.Ar in the cancer-injected limb at 18
days post-injection. Previous studies have demonstrated that
angiogenesis is a necessary process for the growth of MDA-
MB-231 tumour masses in bone and the subsequent osteolysis
[17,35,36]. Interestingly, we observed increased
vascularisation in the cancer-injected limbs at 18 days post-
injection, suggesting that MDA-MB-231 cells were in the early
stages of tumour formation where blood vessels are important
for continual growth.
In our model, the observed bone loss was linked to a marked
reduction in osteoblast activity. Even though the number of
active osteoblasts did not differ significantly (as indicated by no
change in mineralising surface), the rate of bone mineral
deposition of individual osteoblasts (as indicated by mineral
apposition rate) was significantly lower in the cancer-injected
limbs at 36 days post-injection compared to their respective
controls. In addition, our data has shown that osteoclast activity
(as indicated by percentage resorption surface) and osteoclast
number (as indicated by osteoclast number per bone surface)
did not differ significantly between the cancer-injected and
PBS-injected limbs. In fact a trend was observed in our data
where osteoclast number and activity is reduced in the
presence of breast cancer cells. Our results are supported by
Phadke et al. [14] who report a significant decrease in both
osteoclast and osteoblast numbers at 4 weeks post-MDA-
MB-435 cell injection. Taken together, these results suggest
that the observed bone loss in our study was due to decreased
osteoblast activity, rather than increased osteoclast activity.
Our finding is in contrast with experimental findings which
suggest that the increased bone loss was due to increased
osteoclastic activity. A number of in vitro studies have shown
that breast cancer cells secrete a range of factors that
contribute to osteoclast differentiation and proliferation
[12,37-39]. However an increased number of osteoclasts
[12-16] does not necessarily result in an increase in resorption
activity. Moreover, one cannot conclude that the bone loss is
osteoclast-dependent without measurements of the osteoblast
activity, given that a decrease in bone formation activity can
contribute to a reduction in trabecular bone area [25].
Therefore our study, through examination of osteoblast and
osteoclast activity, highlights that it is through a significant
downregulation of osteoblast activity that bone loss in the
breast cancer-induced bone lesion in vivo is induced.
Brown et al. [21] demonstrate that the behaviour of both
osteoblasts and osteoclasts is dependent on the proximity and
size of the breast cancer tumour mass within the bone
microenvironment. Therefore the activity of bone cells changes
with advancing osteolytic progression. This makes cross-study
comparison challenging when results are reported across a
small number of timepoints. The observation of only two mice
exhibiting severe cortical perforations in our study indicates
that the majority of mice were in the early stages of osteolytic
development. As the focus of this study was to measure the
dynamic histomorphometric changes of the osteolysis
development, undecalcified sections were required, limiting the
visibility of adjacent tumour tissue. NuMA (nuclear mitotic
apparatus protein) immunohistochemical staining was
performed in the small sample of paraffin-embedded bones. It
confirmed the presence of small colonies of breast-cancer cells
in the proximal metaphysis of the tibia, supporting that the
majority of mice in our study were in the early stages of
osteolytic disease. Therefore our finding that trabecular bone
loss has developed through a significant retardation of
osteoblast activity, is specific to the early stages of osteolysis.
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Cortical perforations associated with late stage osteolysis and
large tumour colonies that often fill the entire medullary cavity
are likely driven by modulation of osteoclast behaviour [21] but
may occur through resorption by the tumour cells themselves
[14].
The rate of bone turnover did not differ significantly between
the cancer-injected and control limbs at both time-points,
indicating that the observed bone loss could not be a
temporary change associated with increased bone turnover. In
physiological bone remodelling, the removal of old bone matrix
and subsequent filling of resorption pits with new bone can take
approximately 16-20 days in mice [23] and during this
remodelling period the bone tissue can appear to be
undergoing bone loss because the resorption pits are yet to be
filled. However in our model, the reduction in trabecular area
was due to uncoupling of normal bone remodelling evidenced
by the decrease in activity of osteoblasts and unchanged level
of bone resorption, which led to a relatively higher level of bone
degradation activity and the development of an osteolytic
lesion.
Results from the histomorphometric analysis have shown
that the bone loss observed was due to an overall thinning of
the trabecular bone pieces rather than perforation of the bone
tissue matrix. This is supported by our finding that the
osteoclast activity did not differ significantly in the presence of
breast cancer cells. An increase in resorption activity is likely to
perforate the trabecular struts and would have led to increased
trabecular separation [25,40], which was not the case in our
study. In contrast, if each resorption pit was not completely
filled due to insufficient osteoblast activity, then there would be
a gradual thinning of the trabecular bone pieces with time
following each remodelling cycle. Indeed, this is what we have
observed.
Bone loss becomes irreversible when the trabecular pieces
are lost, because there is no platform for the bone-forming
osteoblasts to work on to repair the damaged tissue [25]. New
pieces of trabecular bone can only be formed during
endochondral ossification during the juvenile growth period.
After this point perforations in the bone tissue matrix are
difficult to repair and structural integrity can be permanently
compromised. In this regard, our results have significant
implications because it appears that the bone loss associated
with MDA-MB-231 cell infiltration was due to overall thinning of
each trabecular bone piece, rather than initial perforation of the
trabecular architecture which would have otherwise destroyed
the interconnections between the trabecular bone pieces. This
suggests that, at least in the early stages of the development of
breast cancer bone metastasis where the connectivity in bone
tissue matrix is preserved, the bone loss is theoretically
reversible.
Currently, much research in breast cancer metastasis
focuses on targeting the osteoclast population and/or bone
resorption with the success of therapeutic targets being gauged
by their capacity to control the level of osteoclast activity
[41,42]. Bisphosphonates are the current gold standard of care
for breast cancer patients with bone metastases [43]. They are
a class of anti-catabolic drugs which suppress bone resorption
activity by inducing osteoclast apoptosis or by inhibiting
osteoclast function [44]. Large scale clinical trials have
demonstrated that bisphosphonates reduce tumour burden and
prevent further bone loss in animal models [16,18] as well as
reducing bone pain in patients with breast cancer metastasis
[45] by targeting the tumour cells, angiogenesis and the bone
microenvironment. However the effectiveness of
bisphosphonate treatment in bone metastasis has been
demonstrated to be lower than that seen in osteoporosis
therapy, as soluble factors released from breast cancer cells
can interfere with the action of the bisphosphonate in inducing
osteoclast apoptosis [46]. Furthermore bisphosphonate
treatments merely maintain bone mass without restoring the
bone that has been lost [48] and patients continue to develop
pathologic fractures. This may be because there is insufficient
bone formation activity at the metastatic site to regenerate the
bone which has been lost, as suggested by our findings. Early
clinical trials with denosumab, a human monoclonal antibody
that neutralises receptor activator of NF-kappa-B ligand
(RANKL), have shown promising results with reduced bone
resorption, increased bone mineral density and reduced risk of
fracture in osteoporosis and bone metastasis patients [47].
However despite its FDA approval in 2010, there are ongoing
concerns regarding a high incidence of hospitalisations due to
infections in denosumab trials [48]. RANKL binding is not only
required for osteoclast formation but also immunogenesis and
therefore denosumab may be producing adverse effects in the
differentiation of T and B cells [49]. Much work is therefore still
needed to identify safe and effective treatments for bone
metastasis that target both the bone microenvironment and the
tumour cells directly. In this regard, the administration of
anabolic drugs which stimulate the osteoblasts to increase
rates of new bone formation is one direction that has not been
explored in the treatment of breast cancer bone metastases,
given their potential to stimulate the re-building of bone that
has been lost.
We have demonstrated using real time PCR that the MDA-
MB-231 cell line expresses the mRNA for noggin and DKK-1.
This is consistent with recent studies which have demonstrated
that DKK-1 and noggin are expressed in high levels in human
clinical samples of breast cancer bone metastases
[19,20,48,50], with DKK-1 expression being significantly lower
in osteoblastic metastatic lesions and in breast cancer patients
with non-bone metastases [20]. Previously, the Wnt-antagonist
DKK-1 has been implicated in reduced bone formation activity
in multiple myeloma [28] and in animal models of prostate
cancer bone metastasis [29] where it may regulate the
transition between osteolytic and osteoblastic phenotypes [51].
In fact some studies have indicated that Wnt signalling is not
only important for osteoblastic differentiation but also can
inhibit osteoprotegerin secretion by osteoblasts and therefore
may lead to increased osteoclastic activity [20,50]. In our study
however, we did not observe increased osteoclastic activity
from our histomorphometric analysis. In addition, the BMP-
antagonist noggin appears to facilitate decreased bone
formation in an animal model of prostate cancer bone
metastasis (30) and in a number of osteolytic cell lines in vitro
with prostate-derived cancer cell lines expressing higher levels
of noggin than breast cancer derived cells [52]. Schwaninger et
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al. [52] confirm in their study that through molecular expression
analysis it appears that both inhibition of osteoblast activity and
stimulation of osteoclast recruitment are necessary for the full
expression of the osteolytic metastatic phenotype. Interestingly
Brown et al. [21] have demonstrated that whilst only the
osteoclastic cell populations adjacent to breast cancer cells
were significantly increased, only the osteoblastic cell
populations not in contact with breast cancer cells were
significantly modulated. This suggests contrasting signalling
patterns between bone cell type and breast cancer cells.
Furthermore Bu et al. [50] have demonstrated that the addition
of conditioned media from MDA-MB-231 cells inhibits Wnt3A-
induced osteoblast differentiation of C2C12 cells. Therefore the
tumour-induced osteoblast regulation appears to rely on
secreted factors from the cancer cells, further supporting the
important role of paracrine molecules such as DKK-1 and
Noggin in modulation of osteoblast function by breast cancer
cells. Therefore our results complement these in vitro studies,
where we show for the first time significant down-regulation of
osteoblast activity in the bone remodelling cycle in the
presence of MDA-MB-231 cells in vivo.
It is important to note that the MDA-MB-231 cell line
represents only a subpopulation of breast cancer cells that
have the potential to induce osteolytic bone lesions. Given that
only one cell line was used in this study, it would be premature
to conclude whether our findings using MDA-MB-231 cells
represent the general mechanism through which all osteolytic
bone lesions develop in breast cancer metastases. However
MDA-MB-231 cells are currently the only commercially
available breast cancer cell line that has been shown to induce
purely osteolytic bone changes and have a high metastatic rate
to bone [42,53-56]. In fact to date, there are no breast cancer
cell lines available that are derived directly from a human bone
metastasis [57].
In summary, this study has demonstrated that in our
intratibial injection model of MDA-MB-231 cells in SCID mice,
the osteolytic bone lesion developed through a decrease in
mineral apposition rate and therefore reduced osteoblastic
activity, rather than increased bone resorption as commonly
reported in the literature. This reduction in osteoblast activity is
consistent with the expression of two specific osteoblast
inhibitors, DKK-1 and noggin, in MDA-MB-231 cells. In
addition, we have determined that the cancer-induced bone
loss was due to trabecular thinning rather than perforations of
the bone tissue matrix in the early stages of lesion
development, which suggests that this bone loss may be
reversible. Whilst the osteoblast as a potential therapeutic
target is acknowledged in osteoblastic lesions that are common
in prostate cancer, there is little mention of the importance of
osteoblasts in the development of osteolytic lesions in breast
cancer. Thus, our data have provided novel insights into the
mechanisms through which breast cancer cells induce
osteolytic lesions in bone and may aid in the ongoing
development of appropriate treatments.
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